Advance | $8,550,000 | (Feb 6, 2026)
Turnstile | $29,000,000 | (Feb 6, 2026)
Accrual | $75,000,000 | (Feb 6, 2026)
Certified by Founder
Lodge
Bryleos
start up
United States
- Johnson City, Tennessee
- 14/06/2023
- Seed
- $5,000,000
Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders.
In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical.
Bryleos: More Life While Living
- Industry Biotechnology Research
- Website https://bryleos.com/
- LinkedIn https://www.linkedin.com/company/bryleos/
Connect Music | $80,000,000 | (Feb 6, 2026)
adaption | $50,000,000 | (Feb 6, 2026)
Cadastral | $9,500,000 | (Feb 6, 2026)
Nixtla | $16,000,000 | (Feb 6, 2026)
Nullify | $12,500,000 | (Feb 6, 2026)
Uplift360 | $8,724,008 | (Feb 6, 2026)
Fundamental | $255,000,000 | (Feb 6, 2026)
Duna | $35,365,500 | (Feb 6, 2026)
Flock AI | $6,000,000 | (Feb 6, 2026)